Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community

Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View all publications

Special Issues

Expert Hails <em>NRG1</em> Fusions as the
Expert Hails NRG1 Fusions as the "Next Big Target" in Oncology
Developments in NRG1 Fusion+ Cancers   >   Articles
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
Emerging MOAs in Multiple Myeloma   >   Videos
Dr. Duruisseaux on the Incidence of <em>NRG1</em> Fusions in Solid Tumors
Dr. Duruisseaux on the Incidence of NRG1 Fusions in Solid Tumors
Developments in NRG1 Fusion+ Cancers   >   Videos
Dr. Usmani on DREAMM Trials in Multiple Myeloma
Dr. Usmani on DREAMM Trials in Multiple Myeloma
Emerging MOAs in Multiple Myeloma   >   Videos
Dr. Liu on <em>NRG1</em> Fusions in Oncology
Dr. Liu on NRG1 Fusions in Oncology
Developments in NRG1 Fusion+ Cancers   >   Videos
Case Series Highlights Afatinib Activity in NRG1+ Cancers
Case Series Highlights Afatinib Activity in NRG1+ Cancers
Developments in NRG1 Fusion+ Cancers   >   Articles
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma
Developments in NRG1 Fusion+ Cancers   >   Videos
Dr. Tolba on Targeting NRG1 Fusions With Afatinib
Dr. Tolba on Targeting NRG1 Fusions With Afatinib
Developments in NRG1 Fusion+ Cancers   >   Videos
Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain
Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain
Developments in NRG1 Fusion+ Cancers   >   Articles
Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer
Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer
Developments in NRG1 Fusion+ Cancers   >   Articles
Next Page >>
Publication Bottom Border
Border Publication
 
x